Clinical trials: NSCLC, Squamous or Non-Squamous
Non-small-cell Lung Cancer
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib
The primary objective of this study is to determine if the combination regimen of ARQ 197 with erlotinib will improve overall survival (OS) compared to erlotinib monotherapy in subjects with locally advanced or metastatic…
- Trial name
- ATTENTION (NCT01377376)
- Testing
- ARQ 197 and Erlotinib
- Where
- Japan
- Sponsor
- Kyowa Kirin Co., Ltd.
Lung Cancer
Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as vinorelbine, cisplatin, docetaxel, gemcitabine, and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00863512
- Testing
- cisplatin, docetaxel, gemcitabine hydrochloride
- Where
- 94 sites in United States, Australia
- Volunteers
- 34 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-Small Cell Lung Cancer, Brain Neoplasms
A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)
This was an open-label, multicenter, single-arm, Phase II trial of bevacizumab combined with first- or second-line therapy in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with previously treated…
- Trial name
- NCT00312728
- Testing
- bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents
- Volunteers
- 115 people
- Sponsor
- Genentech, Inc.
Carcinoma, Squamous Cell, Carcinoma, Adenosquamous
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
Determine whether the addition of CP- 751,871 in combination with paclitaxel plus carboplatin prolongs survival in patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV or recurrent) NSCLC of…
- Conditions
- Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT00596830
- Testing
- CP-751,871 (Figitumumab), Carboplatin, Paclitaxel
- Where
- 280 sites in United States, Australia and 24 more
- Volunteers
- 681 people
- Sponsor
- Pfizer
Neoplasms
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and…
- Trial name
- NCT02315066
- Testing
- PF-04518600, PF-04518600 plus PF-05082566
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 174 people
- Sponsor
- Pfizer
Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma
Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer
A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma, Metastatic Non-Squamous Cell Carcinoma
- Trial name
- NCT03847519
- Testing
- ADXS-503, Pembrolizumab
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- Advaxis, Inc.
Lung Neoplasms
Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
Efficacy and Safety Evaluation of IBI308 in Patients with advanced or metastatic Non-squamous NSCLC
- Trial name
- NCT03607539
- Testing
- Sintilimab, Pemetrexed, Platinum
- Where
- China
- Volunteers
- 397 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Lung Cancer
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01041781
- Testing
- carboplatin, celecoxib, gemcitabine hydrochloride
- Where
- 400 sites in United States
- Volunteers
- 313 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non Small Cell Lung Carcinoma, c-MET
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide.
- Trial name
- NCT06772623
- Testing
- Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab
- Where
- 127 sites in United States, Argentina and 15 more
- Volunteers
- 252 people
- Sponsor
- AbbVie
Advanced Solid Tumor, Non-small Cell Lung Cancer
Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
This will be a Phase 1 Open-label, dose escalation and expansion study of MT-6402 (an Engineered Toxin Body (ETB)) in subjects with advanced solid cancer that expresses PD-L1
- Conditions
- Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT04795713
- Testing
- MT-6402
- Where
- 16 sites in United States
- Volunteers
- 64 people
- Sponsor
- Molecular Templates, Inc.
Non-Small Cell Lung Cancer
A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
This is a multicenter, randomized, open-label, controlled phase II clinical study to evaluate the efficacy and safety of HS-20093 injection combined with adebrelimab versus HS-20093 injection in previously treated patients with…
- Trial name
- NCT07824882
- Testing
- HS-20093 for Injection, Adebrelimab Injection
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Hansoh BioMedical R&D Company
Locally Advanced or Metastatic Non-squamous NSCLC, Harboring EGFR Sensitive Mutations NSCLC
A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
This is a Phase 3, randomized, positive-controlled, open-label clinical study. The primary objective is to evaluate the efficacy of JMT101 in combination with osimertinib versus osimertinib alone in patients with newly diagnosed…
- Conditions
- Locally Advanced or Metastatic Non-squamous NSCLC, Harboring EGFR Sensitive Mutations NSCLC, Previously Untreated Systematically NSCLC
- Trial name
- NCT06735391
- Testing
- JMT101, Osimertinib
- Where
- China
- Volunteers
- 516 people
- Sponsor
- Shanghai JMT-Bio Inc.
Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
The purpose of this study is to learn about the safety and the effects of PF-08046037 alone or with sasanlimab for the treatment of certain advanced or metastatic malignancies.
- Conditions
- Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Trial name
- NCT06974734
- Testing
- PF-08046037, sasanlimab
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 8 people
- Sponsor
- Pfizer
Head and Neck Cancer, Lung Cancer
Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00021333
- Testing
- filgrastim, cisplatin, paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 29 people
- Sponsor
- Fox Chase Cancer Center
Solid Tumors
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
The purpose of this study is to assess the safety and antitumor activity of INCB001158 plus epacadostat, with or without pembrolizumab, in participants with advanced or metastatic solid tumors.
- Trial name
- NCT03361228
- Testing
- INCB001158, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incyte Corporation
Non-Small Cell Lung Cancer
A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC
The primary purpose of this research study is to evaluate how safe, how well tolerated and how effective a range of doses of L-DOS47 in combination with standard doublet therapy of pemetrexed/carboplatin in patients with Stage IV…
- Trial name
- NCT02309892
- Testing
- L-DOS47
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Helix BioPharma Corporation
Non-squamous Non-small Cell Lung Cancer
Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
This is a non-randomized, open-label, single arm phase II trial of the combination of bevacizumab and ixabepilone in patients with advanced- or metastatic non-squamous NSCLC progressive after first or second-line therapy.
- Trial name
- NCT01057212
- Testing
- ixabepilone, bevacizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Providence Health & Services
Non-Squamous Non-Small Cell Lung Cancer
An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
This observational study will evaluate modality, efficacy and safety of Avastin (bevacizumab) as first-line treatment in combination with chemotherapy in patients with inoperable advanced, metastatic or recurrent non-squamous…
- Trial name
- NCT01333007
- Where
- 152 sites in France
- Volunteers
- 423 people
- Sponsor
- Hoffmann-La Roche
Locally Advanced or Metastatic Solid Tumors, Squamous-cell Non-small Cell Lung Cancer
HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors
This Phase1, multicenter, first-in-human, open-label, dose-escalation, and dose expansion study will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of HLX35 administered as a single-agent…
- Trial name
- NCT05360381
- Testing
- HLX35
- Where
- 2 sites in China
- Volunteers
- 82 people
- Sponsor
- Shanghai Henlius Biotech
Carcinoma, Non-Small-Cell Lung
A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
This is a trial to evaluate the efficacy, safety, and tolerability of HS-10370 in combination with Platinum-based Doublet Chemotherapy With or Without Adebrelimab Versus Tislelizumab Plus Platinum-based Doublet Chemotherapy as…
- Trial name
- NCT07822542
- Testing
- HS-10370, Adebrelimab, Cisplatin
- Volunteers
- 448 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.